Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects

被引:49
作者
Chen, XP [1 ]
Tan, ZR [1 ]
Huang, SL [1 ]
Huang, Z [1 ]
Ou-Yang, DS [1 ]
Zhou, HH [1 ]
机构
[1] Cent S Univ, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China
关键词
D O I
10.1067/mcp.2003.14
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study was designed to define the effect of low-dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects. Methods: Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified 5-drug cocktail procedure consisting of caffeine, mephenytoin, metoprolol, chlorzoxazone, and midazolam was performed to simultaneously assess in vivo activity of Cyp1A2, CyP2C19, Cyp2D6, CY-P2E1, and CYP3A, respectively. The activities were assessed on 4 occasions including at baseline, after 7 and 14 daily doses of aspirin, and at 7 days after discontinuation of aspirin. Concentrations of parent drugs and corresponding metabolites in biologic samples were assayed by reversed-phase HPLC. Results: Both 7-day and 14-day aspirin intake increased the activity of CYP2C19 significantly, as indicated by 4-hydroxymephenytoin urinary recovery (P < .001). Induction of low-dose aspirin on CYP2C19 was time-dependent. CYP3A activity indices increased moderately but significantly by both 7-day and 14-day aspirin treatment (P < .05), but the percentage changes in CYP3A activity indices were not significant. Low-dose aspirin had no effect on CYP1A2, CYP2D6, and CYP2E1 in vivo activity by either 7-day or 14-day treatment. Conclusions. The effect of low-dose aspirin on CYPs was enzyme-specific. Both 7-day and 14-day low-dose aspirin induced the in vivo activities of CYP2C19 but did not affect the activities of CYP1A2, CYP2D6, and CYP2E1. The effect of low-dose aspirin on CYP3A activity awaits further confirmation. When low-dose aspirin is used in combination with drugs that are substrates of CYP2C19, doses of the latter should be adjusted to ensure their efficacy. (Clin Pharmacol Ther 2003;73:264-71.).
引用
收藏
页码:264 / 271
页数:8
相关论文
共 29 条
[1]   In vivo modulation of CYP enzymes by quinidine and rifampin [J].
Branch, RA ;
Adedoyin, A ;
Frye, RF ;
Wilson, JW ;
Romkes, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (04) :401-411
[2]   Anti-inflammatory drugs protect against Alzheimer disease at low doses [J].
Broe, GA ;
Grayson, DA ;
Creasey, HM ;
Waite, LM ;
Casey, BJ ;
Bennett, HP ;
Brooks, WS ;
Halliday, GM .
ARCHIVES OF NEUROLOGY, 2000, 57 (11) :1586-1591
[3]   EFFECTS OF ACETYLSALICYLIC-ACID ON PARAMETERS RELATED TO PEROXISOME PROLIFERATION IN MOUSE-LIVER [J].
CAI, YO ;
SOHLENIUS, AK ;
ANDERSSON, K ;
SUNDBERG, C ;
DEPIERRE, JW .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (12) :2213-2219
[4]  
Chen JY, 1997, DRUG METAB DISPOS, V25, P1165
[5]   Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate [J].
Damme, B ;
Darmer, D ;
Pankow, D .
TOXICOLOGY, 1996, 106 (1-3) :99-103
[6]   Cytochrome P450 3A - Ontogeny and drug disposition [J].
de Wildt, SN ;
Kearns, GL ;
Leeder, JS ;
van den Anker, JN .
CLINICAL PHARMACOKINETICS, 1999, 37 (06) :485-505
[7]  
Dupont I, 1999, DRUG METAB DISPOS, V27, P322
[8]   Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography [J].
Frye, RF ;
Stiff, DD .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (02) :291-296
[9]   Induction of drug metabolising enzymes - Pharmacokinetic and toxicological consequences in humans [J].
Fuhr, U .
CLINICAL PHARMACOKINETICS, 2000, 38 (06) :493-504
[10]  
Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242